Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer

7Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Objective: Cyclooxygenase-2 (COX-2) has been claimed to play role in carcinogenesis and be related to a bad prognosis in tumours. The aim of this study was to investigate the relationship between COX-2 expression and clinical and pathological parameters in early and advanced stage lung cancer patients. Materials and Methods: A total of 73 patients with lung cancer (27 adenocarcinomas, 33 squamous cell carcinomas, 4 large cell carcinomas and 9 small cell cancer) were analysed retrospectively. COX-2 expression was evaluated by immunohistochemistry in resection materials or lung biopsies. Tumor cells demonstrating more intense staining than smooth muscle and endothelial cells were recorded as COX-2 positive. We investigated the correlation between increased COX-2 expression and histological type of the tumor, the stage of the disease and survival. Results: COX-2 expression was observed in 55% of the adenocarcinomas, 45% of the squamous cell carcinomas and 22% of the small cell carcinomas. No correlation was apparent between COX-2 expression and disease stage, histological type and the survival. Conclusion: The results of this study do not support COX-2 expression as an independent prognostic factor in lung cancer. However, since results of the literature are different, further studies made in larger series are needed.

Cite

CITATION STYLE

APA

Mehmet Turk, H., Camci, C., Sevinc, A., Bukyukberber, S., Sari, I., & Adli, M. (2012). Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer. Asian Pacific Journal of Cancer Prevention, 13(1), 315–318. https://doi.org/10.7314/APJCP.2012.13.1.315

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free